Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1411-1414

  Oguz, Arzu ^a   Aykas, Fatma ^b   Unal, Dilek ^b   Karahan, Samet ^b   Uslu, Emine ^b   Basak, Mustafa ^b   Karaman, Ahmet ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b Kayseri State Hospital of Research and Education   (Turkey)

Author keywords

Hepatitis B; Hepatitis C; Lamuvidine; Malignancy

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA; VIRUS RNA;

ARTICLE; BLOOD; EPIDEMIOLOGY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; LIVER FUNCTION TEST; MALE; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY; VIROLOGY;

DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES;

EID: 84896826296     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1411     Document Type: Article

References (33)

1. Alagozlu H, Ozdemir O, Koksal B, Yilmaz A, Coskun M (2013). Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Asian Pac J Cancer Prev, 14, 5489-94.
2. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999). Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer, 81, 69-74.
3. Arcaini L, Merli M, Passamonti F, et al (2010). Impact of treatment related liver toxicity on the outcome of HCVpositive non-Hodgkin's lymphomas. Am J Hematol, 85, 46-50.
4. Besson C, Canioni D, Lepage E, et al (2006). Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol, 24, 953-60.
5. Cainelli F, Longhi MS, Concia E, Vento S (2001). Failure of lamuvidine therapy for chemotherapy induced reactivation of hepatitis. Am J Gastroenterol, 96, 1651-2.
6. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998). Successful treatment with lamuvidine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol, 9, 385-7.
7. Custer B, Sullivan SD, Hazlet TK, et al (2004). Global epidemiology of hepatitis B virus. J Clin Gastroenterol, 38, 158-68.
8. European Association for the Study of the Liver (2011). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol, 55, 245-64.
9. Gurol E, Saban C, Oral O, Cigdem A, Armagan A (2006). Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol, 21, 299-305.
10. Hwang YY, Liang RH (2010). Hepatitis C in haematological patients. Hepat Res Treat, 2010, 961359.
11. Kanamori H, Fukawa H, Maruta A, et al (1992). Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci, 303, 109-11.
12. Kohrt HE, Ouyang DL, Keeffe EB (2006). Systematic review: lamuvidine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther, 24, 1003-16.
13. Kose S, Olmezoglu A, Gozaydin A, Ece G (2011). Seroprevalence of Hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr, 29, 652-5.
14. Kumagai K, Takagi T, Nakamura S, et al (1997). Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol, 8, 107-9.
15. Lau GK, Yiu HH, Fong DY, et al (2003). Early is superior to deferred preemptive lamuvidine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterol, 125, 1742-9.
16. Lavanchy D (2004). Hepatitis B virus epidemiology, disaese burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107.
17. Long M, Jia W, Li S, et al (2011). A single center, prospective and randomized controlled study: Can the prophylactic use of lamuvidine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat, 127, 705-12.
18. Loomba R, Rowley A, Wesley R, et al (2008). Systematic review: the effect of preventive lamuvidine on Hepatitis B reactivation during chemotherapy. Ann Intern Med, 148, 519-28.
19. Mehmet D, Meliksah E, Serif Y, et al (2005). Prevalence of hepatitis B infection in the southeast region of Turkey: comparison of risk factors in rural and urban areas. Jpn J Infect Dis, 58, 15-9.
20. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996). Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer, 78, 2210-5.
21. Persico M, De Marino F, Russo GD, et al (2002). Efficacy of lamuvidine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood, 99, 724-5.
22. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW (1992). Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer, 28, 1338-9.
23. Steinberg JL, Yeo W, Zhong S, et al (2000). Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: procore/core mutations may play an important role. J Med Virol, 60, 249-55.
24. Ter Borg F, Smorenburg S, de Man RA, et al (1998). Recovery from life threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamuvidine therapy. Dig Dis Sci, 43, 2267-70.
25. Utkan G, Azap A, Muallaoglu S, et al (2006). Hepatitis B and C in cancer patients: case-control study. Int J Hematol Oncol, 16, 103-7.
26. Uzun K, Alici S, Ozbay B, Gencer M, Irmak H (2002). The incidence of hepatitis C virus in patients with lung cancer. Turkish Respiratory J, 3, 91-3.
27. Vento S, Cainelli F, Mirandola F, et al (1996). Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347, 92-3.
28. Yazici Y, Demir N, Cinarka H, Yilmaz H, Altintas N (2010). Seroprevalences of HBV, HCV and HIV among healthcare workers of Trabzon Chest Diseases Hospital. Turkish Bull Hyg Experiment Biol, 67, 27-32.
29. Yeo W, Chan PK, Zhong S, et al (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 62, 299-307.
30. Yeo W, Chan PK, Hui P, et al (2003). Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol, 70, 553-61.
31. Yeo W, Ho WM, Hui P, et al (2004). Use of lamuvidine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat, 88, 209-15.
32. Yeo W, Johnson PJ (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209-20.
33. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM (1998). Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer, 83, 1224-30.